Paper No. ____ Date Original Version Filed: April 4, 2018 Date Corrected Version Filed: April 24, 2018

Filed On Behalf Of: Novartis Pharmaceuticals Corporation

By: Nicholas N. Kallas NKallas@fchs.com; ZortressAfinitorIPR@fchs.com (212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC., AND WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED.

Petitioners,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

Case IPR2017-01592¹ Patent No. 8,410,131

CORRECTED PATENT OWNER'S EXHIBIT LIST 4

¹ IPR2018-00507 has been joined to this proceeding (Paper 29, Apr. 03, 2018)

DOCKET

Exhibit	Description	Abbreviation
2001	Expert Declaration Of Howard A. Burris, III, M.D.	Burris Decl.
2002	Curriculum Vitae Of Howard A. Burris, III, M.D.	Burris C.V.
2003	Laughlin, E.H., <i>Coming To Terms With</i> <i>Cancer: A Glossary Of Cancer-Related Terms</i> , pages 4, 126, 140, 173-174, 188-190 (2002)	Laughlin
2004	Altman, R. & Sarg, M.J., The Cancer Dictionary, 51-52, 278 (1992)	Altman
2005	Sutcliffe, S.B. & Gospodarowicz, M.K., Chapter 25, "Primary Extranodal Lymphomas," <i>The Lymphomas</i> (Canellos, G.P. et al. eds., 1998)	Sutcliffe 1998
2006	Molina, A. & Pezner, R.D., Chapter 30, "Non- Hodgkin's Lymphoma," <i>Cancer Management:</i> <i>A Multidisciplinary Approach: Medical,</i> <i>Surgical, & Radiation Oncology</i> , 4th Edition (Pazdur, R. et al. eds., 2000)	Pazdur
2007	Sutcliffe, S.B. & Gospodarowicz, M.K., "Clinical Features And Management Of Localized Extranodal Lymphomas," <i>Haematological Oncology</i> , Volume 2 pages 189-222 (Keating, A. et al. eds., 1992)	Sutcliffe
2008	Lynch, C.F. & Cohen, M.B., "Urinary System," <i>Cancer</i> 75(1 Suppl.): 316-329 (1995)	Lynch
2009	Ligato, S. et al., "Benign Tumors And Tumor- Like Lesions Of The Adult Kidney Part I: Benign Renal Epithelial Neoplasms," <i>Adv.</i> <i>Anat. Pathol.</i> 6(1): 1-11 (1999)	Ligato

Exhibit	Description	Abbreviation
2010	Glenn, G.M. et al., Chapter 75, "The Molecular Genetics Of Renal Cell Carcinoma," <i>Principles</i> <i>And Practice Of Genitourinary Oncology</i> (Raghavan, D. et al. eds., 1997)	Glenn
2011	Hyland, S. & Wilkinson, D., Chapter 14, "The Nurse Practitioner And The Organization Of Support Services For The Patient With Genitourinary Cancer," <i>Principles And</i> <i>Practice Of Genitourinary Oncology</i> (Raghavan, D. et al. eds., 1997)	Hyland
2012	Vasey, P.A., "Immunotherapy For Renal Carcinoma: Theoretical Basis And Current Standard Of Care," <i>Br. J. Clin. Pharmacol.</i> 50: 521-529 (2000)	Vasey
2013	Kawai, K. et al., "Ex Vivo Gene Therapy Using Granulocyte-Macrophage Colony- Stimulating Factor-Transduced Tumor Vaccines," <i>Mol. Urol.</i> 4(2): 43-46 (2000)	Kawai
2014	Adjei, A.A., "Signal Transduction Pathway Targets For Anticancer Drug Discovery," <i>Cur.</i> <i>Pharm. Design</i> 6: 361-378 (2000)	Adjei
2015	Gordon, M.S. et al., "Phase I Safety And Pharmacokinetic Study Of Recombinant Human Anti-Vascular Endothelial Growth Factor In Patients With Advanced Cancer," <i>J.</i> <i>Clin. Oncol.</i> 19(3): 843-850 (2001)	Gordon
2016	Penn, I. & Starzl, T.E., "Immunosuppression And Cancer," <i>Transplant Proc.</i> 5(1): 943-947 (1973)	Penn
2017	January 19, 2016 Office Action, Prosecution File History Of U.S. Patent Application No. 13/893,537	

0

Exhibit	Description	Abbreviation
2018	January 27, 2016 Office Action, Prosecution File History Of U.S. Patent Application No. 13/893,589	
2019	October 17, 2006 Official Communication and February 26, 2007 Applicant Response (received February 27, 2007), Prosecution File History Of European Patent Application No. 01 903 095.6-2112 (International Application No. PCT/US01/01537)	
2020	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Christina Schwarz Under 37 C.F.R. § 42.10	
2021	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Charlotte Jacobsen Under 37 C.F.R. § 42.10	
2022	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Susanne L. Flanders Under 37 C.F.R. § 42.10	
2023	Kozlowski, J.M. et al., Chapter 78, "Renal Cell Carcinoma, Tumor Markers," <i>Principles And</i> <i>Practice Of Genitourinary Oncology</i> (Raghavan, D. et al. eds., 1997)	Kozlowski
2024	Motzer, R.J. & Russo, P., "Systemic Therapy For Renal Cell Carcinoma," <i>J. Urology</i> 163:408-417 (2000)	Russo
2025	Physicians' Desk Reference, 55th Edition (2001), pages 3443-3448 (Entry for Rapamune® Oral Solution (Sirolimus))	Rapamune® PDR

2

Exhibit	Description	Abbreviation
2026	Document Stamped At The March 13, 2018 Deposition Of Dr. Allan J. Pantuck	
2027	March 13, 2018 Deposition Testimony of Dr. Allan J. Pantuck	Pantuck
2028	Truong, L. et al., "The Diagnostic and Therapeutic Roles of Fine-Needle Aspiration," <i>Am. J. Clin. Pathol.</i> 115:18-31 (2001)	Truong
2029	Hanahan, D. & R.A. Weinberg, "The Hallmarks of Cancer," <i>Cell</i> 100:57-70 (2000)	Hanahan
2030	Abbas, Z. et al., "Renal lymphoma: an unusual cause of extrahepatic biliary obstruction," <i>Postgraduate Med. J.</i> 617-18 (1996)	Abbas
2031	"Genitourinary," Stedman's Medical Dictionary 738-39 (27 th ed. 2000)	Stedman's
2032	Braybrooke, J.P. et al., "A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis," <i>Clin. Cancer Res.</i> 6:4697-4704 (2000)	Braybrooke
2033	"Proleukin [®] ," <i>Physicians' Desk Reference</i> [®] , 874-78 (47 th ed. 1993)	Proleukin [®] PDR
2034	Yagoda, A. et al., "Chemotherapy for Advanced Renal-Cell Carcinoma: 1983-1993," <i>Seminars Oncol.</i> 22(1):42-60 (1995)	Yagoda

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.